Key Highlights

● The stock's roughly 7.7% slide in the latest session does not map to a single, separately verified same-day catalyst.

● Aardvark Therapeutics, Inc. is developing ARD-101, an oral small molecule that activates bitter taste receptors, as a treatment for hyperphagia, the extreme, persistent hunger that defines Prader-Willi syndrome.

● Aardvark recently traded near $4.92, down about 7.7%, giving it a market Capitalization of roughly $107.7 million, according to market data.

● The pivotal item is the unblinding of the HERO and open-label extension data, which management has signaled for the second half of 2026 and which will inform whether ARD-101 can proceed.

Company and Latest Development

Aardvark Therapeutics (NASDAQ:AARD), Inc. is developing ARD-101, an oral small molecule that activates bitter taste receptors, as a treatment for hyperphagia, the extreme, persistent hunger that defines Prader-Willi syndrome. After listing in February 2025, the company advanced ARD-101 into the Phase 3 HERO trial. In late February 2026, it announced a voluntary pause of HERO enrollment following reversible cardiac observations at above-target doses in volunteer studies. Then, on May 14, 2026, it disclosed that the FDA had placed a full clinical hold on the ARD-101 investigational new drug application, and said it would unblind HERO and open-label extension data to inform a path forward.

What Is Driving Attention Around AARD?

The stock's roughly 7.7% slide in the latest session does not map to a single, separately verified same-day catalyst. Instead, attention is anchored to the clinical hold and its fallout: multiple Shareholder class-action suits have been filed alleging investor losses, and the market is awaiting the unblinded HERO and open-label data that management flagged for later in 2026. In a small biotech operating under a clinical hold, day-to-day moves often reflect positioning ahead of that binary event rather than fresh news.

Key Numbers and Company Position

Aardvark recently traded near $4.92, down about 7.7%, giving it a market capitalization of roughly $107.7 million, according to market data. The company reported about $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, and a net loss of roughly $14.4 million for the second quarter, per its August 2026 results. The IPO priced on February 13, 2025. That cash balance provides a cushion, but the value of the Franchise hinges almost entirely on the fate of ARD-101.

What Could Come Next?

The pivotal item is the unblinding of the HERO and open-label extension data, which management has signaled for the second half of 2026 and which will inform whether ARD-101 can proceed. Investors may watch for FDA interactions that could lift or modify the clinical hold, updates on the earlier-stage ARD-201 program, cash-runway commentary, and developments in the shareholder litigation.

Risks to Watch

Clinical and Regulatory Risk is front and center: the hold may not be lifted, and the HERO data could disappoint. A cardiac safety signal raises the bar for any restart. Litigation adds cost and uncertainty, and as a loss-making clinical-stage biotech, Aardvark will likely need additional capital in time, raising dilution risk despite its current cash. Heavy reliance on a single lead asset magnifies the impact of each outcome.

Aardvark Therapeutics, Inc's Near-Term Catalysts Now Matter

Aardvark Therapeutics embodies the binary nature of single-asset biotech: a promising rare-disease target overshadowed by a safety-driven clinical hold and mounting litigation. With a meaningful cash cushion but a program on pause, the developments to monitor are the unblinded HERO and open-label readout, any FDA decision on the hold, and the company's next strategic and financing steps. Until that data arrives, AARD is likely to remain volatile, with sentiment swinging on regulatory and legal headlines.